Fast Biopharma

FasT Biopharma is a private, preclinical-stage biotech developing novel anti-FasL antibodies to inhibit pathological cell death. Its lead programs target high-need areas in ophthalmology (glaucoma, dry AMD) and oncology (colorectal cancer), aiming to preserve vision and enhance anti-tumor immunity. The company leverages a deep understanding of the Fas/FasL biology to engineer antibodies tailored for specific routes of administration and disease settings, positioning it to address significant unmet medical needs across multiple therapeutic areas.

Platform for developing highly potent, neutralizing monoclonal antibodies against Fas ligand (FasL), engineered for specific disease settings and routes of administration (e.g., intravitreal, intravenous with extended half-life).

In ophthalmology, competitors include companies developing neuroprotectants for glaucoma (e.g., Nicox, Aerie Pharma) and complement inhibitors/other therapies for geographic atrophy (e.g., Apellis, Iveric Bio). In oncology, the competitive field is vast, with numerous companies developing T-cell engagers, next-gen checkpoint inhibitors, and other immuno-oncology agents. FasT Biopharma's specific focus on FasL-mediated T-cell deletion is a relatively niche, novel approach.